Does the media refer more to MPLT or NKTR?

In the previous week, Nektar Therapeutics had 3 more articles in the media than Maplight Therapeutics. MarketBeat recorded 5 mentions for Nektar Therapeutics and 2 mentions for Maplight Therapeutics. Maplight Therapeutics' average media sentiment score of 0.51 beat Nektar Therapeutics' score of 0.11 indicating that Maplight Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maplight Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nektar Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, VERA or MPLT?

Vera Therapeutics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vera Therapeutics N/A N/A -$299.61M -$5.86 N/A Maplight Therapeutics N/A N/A -$161.15M -$42.31 N/A

Is VERA or MPLT more profitable?

Vera Therapeutics' return on equity of -84.13% beat Maplight Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Vera Therapeutics N/A -84.13% -66.79% Maplight Therapeutics N/A -98.60% -60.33%

Does the media prefer VERA or MPLT?

In the previous week, Vera Therapeutics had 23 more articles in the media than Maplight Therapeutics. MarketBeat recorded 25 mentions for Vera Therapeutics and 2 mentions for Maplight Therapeutics. Vera Therapeutics' average media sentiment score of 0.65 beat Maplight Therapeutics' score of 0.51 indicating that Vera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vera Therapeutics 9 Very Positive mention(s) 5 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Maplight Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, PHVS or MPLT?

Pharvaris is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pharvaris N/A N/A -$198.79M -$3.05 N/A Maplight Therapeutics N/A N/A -$161.15M -$42.31 N/A

Is PHVS or MPLT more profitable?

Pharvaris' return on equity of -61.40% beat Maplight Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Pharvaris N/A -61.40% -56.00% Maplight Therapeutics N/A -98.60% -60.33%

Does the media refer more to PHVS or MPLT?

In the previous week, Pharvaris had 23 more articles in the media than Maplight Therapeutics. MarketBeat recorded 25 mentions for Pharvaris and 2 mentions for Maplight Therapeutics. Pharvaris' average media sentiment score of 0.53 beat Maplight Therapeutics' score of 0.51 indicating that Pharvaris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 13 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maplight Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PGEN or MPLT?

In the previous week, Precigen had 4 more articles in the media than Maplight Therapeutics. MarketBeat recorded 6 mentions for Precigen and 2 mentions for Maplight Therapeutics. Precigen's average media sentiment score of 0.85 beat Maplight Therapeutics' score of 0.51 indicating that Precigen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precigen 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maplight Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NUVB or MPLT?

In the previous week, Nuvation Bio had 15 more articles in the media than Maplight Therapeutics. MarketBeat recorded 17 mentions for Nuvation Bio and 2 mentions for Maplight Therapeutics. Maplight Therapeutics' average media sentiment score of 0.51 beat Nuvation Bio's score of 0.39 indicating that Maplight Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 4 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Maplight Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Maplight Therapeutics (MPLT) Competitors

$10.92 -0.40 (-3.53%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$10.88 -0.04 (-0.37%)

As of 09/18/2026 07:36 PM Eastern

Compare

MPLT vs. NKTR, VERA, PHVS, PGEN, and NUVB

Should you buy Maplight Therapeutics stock or one of its competitors? Maplight Therapeutics's main competitors and comparable companies include Nektar Therapeutics (NKTR), Vera Therapeutics (VERA), Pharvaris (PHVS), Precigen (PGEN), and Nuvation Bio (NUVB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Maplight Therapeutics compare to Nektar Therapeutics?

Maplight Therapeutics (NASDAQ:MPLT) and Nektar Therapeutics (NASDAQ:NKTR) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, media sentiment, profitability, valuation and dividends.

Maplight Therapeutics has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -287.84%. Nektar Therapeutics' return on equity of -37.87% beat Maplight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	-98.60%	-60.33%
Nektar Therapeutics	-287.84%	-37.87%	-25.67%

75.9% of Nektar Therapeutics shares are owned by institutional investors. 3.8% of Maplight Therapeutics shares are owned by company insiders. Comparatively, 2.5% of Nektar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Maplight Therapeutics has higher earnings, but lower revenue than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$42.31	N/A
Nektar Therapeutics	$55.23M	41.48	-$164.08M	-$6.70	N/A

In the previous week, Nektar Therapeutics had 3 more articles in the media than Maplight Therapeutics. MarketBeat recorded 5 mentions for Nektar Therapeutics and 2 mentions for Maplight Therapeutics. Maplight Therapeutics' average media sentiment score of 0.51 beat Nektar Therapeutics' score of 0.11 indicating that Maplight Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maplight Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nektar Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Maplight Therapeutics currently has a consensus target price of $29.50, suggesting a potential upside of 170.15%. Nektar Therapeutics has a consensus target price of $141.50, suggesting a potential upside of 110.88%. Given Maplight Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Maplight Therapeutics is more favorable than Nektar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	2.94
Nektar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Summary

Maplight Therapeutics beats Nektar Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Maplight Therapeutics compare to Vera Therapeutics?

Vera Therapeutics (NASDAQ:VERA) and Maplight Therapeutics (NASDAQ:MPLT) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

Vera Therapeutics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.86	N/A
Maplight Therapeutics	N/A	N/A	-$161.15M	-$42.31	N/A

99.2% of Vera Therapeutics shares are owned by institutional investors. 15.9% of Vera Therapeutics shares are owned by insiders. Comparatively, 3.8% of Maplight Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Vera Therapeutics had 23 more articles in the media than Maplight Therapeutics. MarketBeat recorded 25 mentions for Vera Therapeutics and 2 mentions for Maplight Therapeutics. Vera Therapeutics' average media sentiment score of 0.65 beat Maplight Therapeutics' score of 0.51 indicating that Vera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vera Therapeutics	9 Very Positive mention(s)	5 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Maplight Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vera Therapeutics presently has a consensus price target of $80.15, indicating a potential upside of 135.75%. Maplight Therapeutics has a consensus price target of $29.50, indicating a potential upside of 170.15%. Given Maplight Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Maplight Therapeutics is more favorable than Vera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Maplight Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	2.94

Vera Therapeutics' return on equity of -84.13% beat Maplight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vera Therapeutics	N/A	-84.13%	-66.79%
Maplight Therapeutics	N/A	-98.60%	-60.33%

Summary

Vera Therapeutics beats Maplight Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Maplight Therapeutics compare to Pharvaris?

Pharvaris (NASDAQ:PHVS) and Maplight Therapeutics (NASDAQ:MPLT) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

Pharvaris' return on equity of -61.40% beat Maplight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-61.40%	-56.00%
Maplight Therapeutics	N/A	-98.60%	-60.33%

Pharvaris currently has a consensus price target of $59.87, indicating a potential upside of 64.60%. Maplight Therapeutics has a consensus price target of $29.50, indicating a potential upside of 170.15%. Given Maplight Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Maplight Therapeutics is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Maplight Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	2.94

Pharvaris is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.05	N/A
Maplight Therapeutics	N/A	N/A	-$161.15M	-$42.31	N/A

In the previous week, Pharvaris had 23 more articles in the media than Maplight Therapeutics. MarketBeat recorded 25 mentions for Pharvaris and 2 mentions for Maplight Therapeutics. Pharvaris' average media sentiment score of 0.53 beat Maplight Therapeutics' score of 0.51 indicating that Pharvaris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	13 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maplight Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Pharvaris beats Maplight Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Maplight Therapeutics compare to Precigen?

Precigen (NASDAQ:PGEN) and Maplight Therapeutics (NASDAQ:MPLT) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

In the previous week, Precigen had 4 more articles in the media than Maplight Therapeutics. MarketBeat recorded 6 mentions for Precigen and 2 mentions for Maplight Therapeutics. Precigen's average media sentiment score of 0.85 beat Maplight Therapeutics' score of 0.51 indicating that Precigen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precigen	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maplight Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Maplight Therapeutics has lower revenue, but higher earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precigen	$9.68M	286.53	-$250.64M	-$1.04	N/A
Maplight Therapeutics	N/A	N/A	-$161.15M	-$42.31	N/A

33.5% of Precigen shares are owned by institutional investors. 41.4% of Precigen shares are owned by insiders. Comparatively, 3.8% of Maplight Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Precigen currently has a consensus target price of $14.50, suggesting a potential upside of 86.38%. Maplight Therapeutics has a consensus target price of $29.50, suggesting a potential upside of 170.15%. Given Maplight Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Maplight Therapeutics is more favorable than Precigen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precigen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Maplight Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	2.94

Maplight Therapeutics has a net margin of 0.00% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 423.75% beat Maplight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precigen	-183.98%	423.75%	84.39%
Maplight Therapeutics	N/A	-98.60%	-60.33%

Summary

Precigen beats Maplight Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Maplight Therapeutics compare to Nuvation Bio?

Nuvation Bio (NYSE:NUVB) and Maplight Therapeutics (NASDAQ:MPLT) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

61.7% of Nuvation Bio shares are owned by institutional investors. 30.1% of Nuvation Bio shares are owned by company insiders. Comparatively, 3.8% of Maplight Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Nuvation Bio had 15 more articles in the media than Maplight Therapeutics. MarketBeat recorded 17 mentions for Nuvation Bio and 2 mentions for Maplight Therapeutics. Maplight Therapeutics' average media sentiment score of 0.51 beat Nuvation Bio's score of 0.39 indicating that Maplight Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvation Bio	4 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Maplight Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nuvation Bio presently has a consensus price target of $13.00, suggesting a potential upside of 122.79%. Maplight Therapeutics has a consensus price target of $29.50, suggesting a potential upside of 170.15%. Given Maplight Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Maplight Therapeutics is more favorable than Nuvation Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Maplight Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	2.94

Maplight Therapeutics has lower revenue, but higher earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$62.90M	32.57	-$204.63M	-$0.44	N/A
Maplight Therapeutics	N/A	N/A	-$161.15M	-$42.31	N/A

Maplight Therapeutics has a net margin of 0.00% compared to Nuvation Bio's net margin of -88.18%. Nuvation Bio's return on equity of -46.59% beat Maplight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-88.18%	-46.59%	-22.01%
Maplight Therapeutics	N/A	-98.60%	-60.33%

Summary

Nuvation Bio beats Maplight Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Maplight Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MPLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MPLT vs. The Competition

Export

Metric	Maplight Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$506.45M	$3.90B	$7.24B	$13.19B
Dividend Yield	N/A	3.64%	2.57%	12.81%
P/E Ratio	-0.26	14.23	275.49	25.40
Price / Sales	N/A	1,419.61	646.01	89.45
Price / Cash	N/A	108.90	76.25	51.42
Price / Book	1.08	15.45	10.46	6.33
Net Income	-$161.15M	-$22.86M	$3.49B	$358.33M
7 Day Performance	-16.00%	-1.21%	0.59%	1.12%
1 Month Performance	-2.76%	-3.29%	-1.74%	-2.39%
1 Year Performance	N/A	37.74%	18.13%	5.35%

Maplight Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MPLT Maplight Therapeutics	2.7955 of 5 stars	$10.92 -3.5%	$29.50 +170.1%	N/A	$506.45M	N/A	N/A	133	High Trading Volume
NKTR Nektar Therapeutics	2.6462 of 5 stars	$73.32 -2.8%	$141.50 +93.0%	+21.7%	$2.58B	$55.23M	N/A	220	News Coverage Analyst Forecast
VERA Vera Therapeutics	2.8089 of 5 stars	$33.78 -4.3%	$80.15 +137.3%	+32.9%	$2.54B	N/A	N/A	40	Analyst Forecast Insider Trade Options Volume
PHVS Pharvaris	3.7296 of 5 stars	$37.74 -0.3%	$59.21 +56.9%	+43.4%	$2.48B	N/A	N/A	30	Positive News Insider Trade
PGEN Precigen	4.1934 of 5 stars	$6.80 -1.0%	$14.50 +113.2%	+107.5%	$2.45B	$9.68M	N/A	190	Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MPLT) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Maplight Therapeutics (MPLT) Competitors

MPLT vs. NKTR, VERA, PHVS, PGEN, and NUVB

How does Maplight Therapeutics compare to Nektar Therapeutics?

Summary

How does Maplight Therapeutics compare to Vera Therapeutics?

Summary

How does Maplight Therapeutics compare to Pharvaris?

Summary

How does Maplight Therapeutics compare to Precigen?

Summary

How does Maplight Therapeutics compare to Nuvation Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MPLT vs. The Competition

Maplight Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Maplight Therapeutics (MPLT) Competitors

MPLT vs. NKTR, VERA, PHVS, PGEN, and NUVB

How does Maplight Therapeutics compare to Nektar Therapeutics?

Is MPLT or NKTR more profitable?

Do insiders and institutionals hold more shares of MPLT or NKTR?

Which has preferable earnings & valuation, MPLT or NKTR?

Does the media refer more to MPLT or NKTR?

Do analysts prefer MPLT or NKTR?

Summary

How does Maplight Therapeutics compare to Vera Therapeutics?

Which has better earnings and valuation, VERA or MPLT?

Do insiders & institutionals believe in VERA or MPLT?

Does the media prefer VERA or MPLT?

Do analysts recommend VERA or MPLT?

Is VERA or MPLT more profitable?

Summary

How does Maplight Therapeutics compare to Pharvaris?

Is PHVS or MPLT more profitable?

Do analysts recommend PHVS or MPLT?

Which has preferable valuation & earnings, PHVS or MPLT?

Does the media refer more to PHVS or MPLT?

Summary

How does Maplight Therapeutics compare to Precigen?

Does the media prefer PGEN or MPLT?

Which has preferable earnings & valuation, PGEN or MPLT?

Do insiders & institutionals hold more shares of PGEN or MPLT?

Do analysts rate PGEN or MPLT?

Is PGEN or MPLT more profitable?

Summary

How does Maplight Therapeutics compare to Nuvation Bio?

Do institutionals and insiders have more ownership in NUVB or MPLT?

Does the media refer more to NUVB or MPLT?

Do analysts recommend NUVB or MPLT?

Which has stronger valuation and earnings, NUVB or MPLT?

Is NUVB or MPLT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MPLT vs. The Competition

Maplight Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools